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Objectives: To investigate the impact of increasing
sample of records reviewed bi-weekly with the Global
Trigger Tool method to identify adverse events in
hospitalised patients.
Design: Retrospective observational study.
Setting: A Norwegian 524-bed general hospital trust.
Participants: 1920 medical records selected from
1 January to 31 December 2010.
Primary outcomes: Rate, type and severity of
adverse events identified in two different samples sizes
of records selected as 10 and 70 records, bi-weekly.
Results: In the large sample, 1.45 (95% CI 1.07 to
1.97) times more adverse events per 1000 patient days
(39.3 adverse events/1000 patient days) were identified
than in the small sample (27.2 adverse events/1000
patient days). Hospital-acquired infections were the
most common category of adverse events in both the
samples, and the distributions of the other categories
of adverse events did not differ significantly between
the samples. The distribution of severity level of
adverse events did not differ between the samples.
Conclusions: The findings suggest that while the
distribution of categories and severity are not
dependent on the sample size, the rate of adverse
events is. Further studies are needed to conclude if the
optimal sample size may need to be adjusted based on
the hospital size in order to detect a more accurate rate
of adverse events.
INTRODUCTION
For more than a decade, considerable efforts
have been invested across healthcare to
reduce adverse events, resulting in many efforts
to identify reliable and valid tools to measure
such events. The Institute for Healthcare
Improvement (IHI) Global Trigger Tool is a
widely used and considered an effective tool
for measuring adverse events.1–3 The method
includes reviewing bi-weekly samples of 10
patient records selected randomly from the
hospital discharge lists. Two non-physician
reviewers search independently for prede-
fined triggers that could indicate possible
adverse events. A physician authenticates
their consensus on the presence of adverse
events and severity. The adverse events iden-
tified in the bi-weekly periods provide data
for Statistical Process Control (SPC) charts
used to analyse adverse events rates over time.
However, concerns have been raised2 4–8
about the method’s ability to accurately detect
rates of adverse events and changes in rates,
due to the small sample size of 10 records
bi-weekly recommended in the IHI method.
In Norway, all hospital trusts are required
by the National Health Authority to use a
translated version of the Global Trigger Tool
to review a minimum of 10 records selected
continuously and bi-weekly in order to
monitor the rates of adverse events in each
hospital trust and at a national level.9 Good
et al10 suggest that sample size should be
Strengths and limitations of this study
▪ The samples were similar in terms of age, sex
and length of stay.
▪ Preventability of the adverse events was not
assessed.
▪ Only two sample sizes were compared.
▪ Method for authentication of events differed
slightly for each set of samples, however, high
inter-rater reliability between the review teams
indicates consistency and thus did not likely
affect the results.
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adjusted to hospital size and based on this, we increased
the sample size at our trust to seven times greater than
that required by the Health Authority, as we believed
this would detect a more accurate rate of adverse events.
Our rates of adverse events have been higher than other
comparable trusts that are reviewing bi-weekly samples
of 10 records, thus we sought to assess whether our
higher rates were due to the larger sample size. The
impact of sample size on adverse event rates has not
been validated to our knowledge, thus demonstrating
the need for this study.
Our aim was to obtain the rate, category and severity of
the identified adverse events in two different sample sizes
of records selected from the same population bi-weekly:
one sample corresponding to the IHI recommendation
and one sample seven times larger. We hypothesised that
increasing the sample size would not yield a different
rate of adverse events per 1000 patient days.
METHODS
Study design
The study is an observational cross-sectional study
including retrospective record review of two samples of
records, 1680 and 240, respectively (figure 1).
Setting
The study was performed in a 524-bed hospital trust at
three geographical locations in Nordland County,
North-Norway. Both the samples were selected from the
same population discharged from 1 January to 31
December 2010. However, the large sample was first
stratified according to discharges from the nine services
in the trust and then 10 records were selected from 5
services and 5 records from 4 services, respectively, for a
total of 70 records bi-weekly. The small sample included
10 records selected bi-weekly from the aggregated dis-
charge lists of all the 9 services. Following the IHI guide-
lines, records were excluded in both samples for
patients aged 17 years or younger, patients admitted pri-
marily for psychiatric or rehabilitation care, or patients
with a length of stay less than 24 h. The whole hospital-
isation was reviewed including patient days at all services
not only at the index service.
The study was approved by the data protection official
in Nordland Hospital trust and by the Norwegian
Regional Ethics Committee (ref 2012/1691).
Record review method
Training of the reviewers followed the IHI recommenda-
tions and included theory, practical review exercises, and
debriefing sessions provided by experienced reviewers.
The IHI definition of an adverse event was used, that is1:
‘Unintended physical injury resulting from or contribu-
ted to by medical care that requires additional monitor-
ing, treatment or hospitalisation, or that results in
death’. Both adverse events associated with treatment
given prior, during or after (within 30 days) to the index
Figure 1 Overview of the study design. Non-physician reviewers; reviewer A and B, physician reviewers; reviewer C and D.
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discharge (the discharge selected from the discharge
lists of the services) were included to evaluate the total
number of adverse events resulting from medical care.
Preventability of the identified adverse events was not
evaluated.
The identified adverse events were grouped into 23
categories derived from the Norwegian translation11 of
the IHI Global Trigger Tool. These categories were
further aggregated into eight main categories (ie,
hospital-acquired infections, surgical complications,
bleeding/thrombosis, patient fall/fracture, medication
harm, obstetric harm, pressure ulcer and other). The
severity of adverse events was categorised into five levels
(E–I) using definitions adapted from those of the
National Coordinating Council for Medication Error
Reporting and Prevention Index (NCC MERP):12
Category E: Temporary harm to the patient and
required intervention
Category F: Temporary harm to the patient and
required initial or prolonged hospitalisation
Category G: Permanent patient harm
Category H: Intervention required to sustain life
Category I: Patient death
The review process for both sets of samples followed
the IHI method,1 where reviewers checked each record
for the presence of triggers from a standard list of trig-
gers in the Norwegian translation of the Global Trigger
Tool. When a trigger was identified, they checked for
documentation indicating that an adverse event had
occurred; for any adverse event detected, whether by a
trigger or not, one of the above eight categories and a
severity level was assigned. The process for authentica-
tion of adverse events differed slightly between the two
sets of samples. For the small samples, two nurses
(reviewer A and reviewer B) reviewed all records inde-
pendently and then together reached consensus on
presence, category and severity of adverse events. A phys-
ician (reviewer C) then authenticated their findings.
The reviewing process of authentication with records
from the large samples was slightly different in that each
record was reviewed by one reviewer—either a nurse
(reviewer A) or one of two physicians (reviewers C and
D). The three reviewers discussed their findings and
reached consensus of presence, category and severity of
adverse events identified (figure 1). The modification
with only one reviewer per record in the reviewing
process for the large samples was due to limited
resources available.
Statistical analysis
Demographic variables of the records were obtained.
Categorical variables were compared between the
samples with χ2 test while continuous variables were
compared using the independent t test.
SPC charts are used to evaluate variations between
data points over time, which is a recommended
approach for evaluating the rates of adverse events
measured by the Global Trigger Tool.1 13 We used QI
Macros in Excel 2013 to present the calculated rate of
adverse events per 1000 patient days in U-charts and the
calculated percentage of records with adverse events in a
P-chart of both samples.14 Test 1–3 of special cause vari-
ation (SCV) were applied in order to evaluate the rates.
The tests are positive if data points are outside the
control limits, eight or more data points are on the same
side of the median or/and if six data points are either
ascending or descending. We hypothesised that different
rates of adverse events in the two samples would yield dif-
ferent results in terms of the tests and control limits.
To compare the calculated rates, proportions of sever-
ities and categories of adverse events between the
samples, we used Poisson regression in generalised
linear models to calculate the relative risk of adverse
events between the samples as the risk ratio (RR).
Poisson regression was chosen as it accounts for varia-
tions in the number of cases reviewed and variations in
the length of stay. The number of adverse events was set
as the dependent variable and log patient days as the
offset variable (in the analysis of adverse events per
patient day). When analysing adverse events per records
and percentages of records with an adverse event, zero
was set as the fixed value. A p value of <0.05 was defined
as statistically significant. We also adjusted for services
and variables associated with the index service.
Associations between adverse events and demographic
variables were explored using Pearson′s correlation and
logistic regression. To assess the inter-rater reliability
between the review teams of the two samples, we used κ
and weighted κ statistics. The following interpretations
from Landis and Koch was used for the Cohen κ coeffi-
cient: poor (<0.0), slight (0.00–0.20), fair (0.21–0.40),
moderate (0.41–0.60), substantial (0.61–0.80) and
almost perfect (0.81–1.00).15 We used SPSS (V.22.0;
SPSS Chicago, Illinois, USA) for statistical analyses.
RESULTS
Demographics characteristics
A total of 1920 records were reviewed in the study using
the Global Trigger Tool. Demographic characteristics in
the samples and the overall population from which the
samples were drawn from are shown in table 1. A total
of 12% of the overall population (14 267 discharges) was
reviewed in the large samples, while 2% was reviewed in
the small sample. Length of stay, age and sex were
derived for the whole hospitalisation and these did not
differ between the large and the small sample. Patients
in the large sample were different to the overall popula-
tion in terms of sex and length of stay while patients in
the small sample did not differ from the overall popula-
tion. Type of admissions (acute or planned), case mix
(discharge diagnose), services (functional units), case
mix index, admission to surgery and numbers of trans-
fers were derived from the index discharge (source of
the random selection) and adjusted for.
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Comparison of adverse events
In the large sample of 1680 records comprising 11 367
patient days, we identified 447 adverse events in 347 dis-
charges. This corresponds to a rate of 39.3 adverse
events per 1000 patient days (95% CI 35.8 to 43.1,
SE=1.86) or 26.6 adverse events per 100 discharges
(95% CI 24.3 to 29.2, SE=1.26). The percentage of
patients with an adverse event was 20.5% in the large
sample. In the small sample of 240 records comprising
1657 patient days, we identified 45 adverse events in 30
discharges. This corresponds to a rate of 27.2 adverse
events per 1000 patient days (95% CI 20.3 to 36.4,
SE=4.05) or 18.8 adverse events per 100 discharges
(95% CI 14.0 to 25.1, SE=2.80). The percentage of
patients experiencing an adverse event was 12.5%. Some
patients experienced more than one adverse event.
Patients experiencing adverse events had longer hospital
stays (large sample r²=0.21, p<0.001 and small sample
r²=0.46, p<0.001) than patients without experiencing
adverse events. In the large sample age correlated
(r²=0.03, p<0.001) with number of adverse events, while
in the small sample age did not correlate with number
of adverse events (r²=−0.003, p=0.54).
The rate of adverse events per 1000 patient days was
45% higher in the large sample than in the small
sample (RR=1.45, 95% CI 1.07 to 1.97; p=0.02).
Likewise, the rate of adverse events per record was 42%
higher in the large sample than in the small sample
(RR=1.42, 95% CI 1.04 to 1.93, p=0.03). The percentage
of records including an adverse event was 65% higher in
the large sample than in the small sample (RR=1.65,
95% CI 1.14 to 2.34, p=0.008). In figure 2, the rates of
adverse events per 1000 patient days in both samples are
presented in control U-charts and percentages of
records with adverse events in control P-charts over the
24 bi-weekly periods in 2010. In both charts, the control
limits are much wider in the small sample than in the
large sample. SCVs (positivity of tests 1) were identified
only for the small sample. This is marked with a black
dot in the U-chart. None of the other tests were positive
for either of the samples.
To adjust for the stratification made before selection
of records to the large sample, we adjusted for the vari-
ables that were associated from the index discharge. The
primary results did not alter as the RR was 1.83 (95% CI
1.32 to 2.54, p<0.001) of identifying an adverse event
per 1000 patient days in the large sample compared
with the small sample when adjusting for these variables.
The inter-rater reliability of the two teams that
reviewed the different sets of samples was obtained to














n 1680 240 14 267
Length of stay (days)* 6.8 (7.5) 6.9 (11.1) 6.3 (6.9) 0.852 0.014 0.400†
Average age (years)* 62 (21) 61 (21) 62 (21) 0.487 0.592 0.344†
Sex (percent women)‡ 62 59 57 0.446 <0.001 0.410§
n.s=non-significant=p value>0.05.
*Values presented as mean with SDs.
†t test.
‡Values presented as percent.
§χ2 test.
Figure 2 Comparison of statistical process control charts (U-chart) and (P-chart) between large and small samples. Dashed line
= upper control limits; dotted line = lower control limits.
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assess for possible impact from the different authentica-
tion processes. The two review teams reviewed a set of
50 patient records, and agreement regarding the pres-
ence of adverse events (κ =0.75), number of adverse
events (κ=0.68) and severity level (κ=0.69) was
substantial.
Hospital-acquired infections were the most frequent
category of identified adverse events in both samples.
There were no significant differences between the esti-
mated proportions of identified adverse events between
the samples for the six main categories of adverse
events; hospital-acquired infections (RR=1.52, 95% CI
0.94 to 2.47, p=0.09), surgical complications (RR=1.28,
95% CI 0.67 to 2.47, p=0.46), bleeding/thrombosis
(RR=1.44, 95% CI 0.70 to 2.98, p=0.33), medication
harm (RR=1.68, 95% CI 0.60 to 4.66, p=0.32), patient
fall (RR=0.83, 95% CI 0.24 to 2.82, p=0.76) and pressure
ulcers (RR=0.73, 95% CI 0.16 to 3.33, p=0.68) (see
online supplementary file 1). For the categories obstet-
ric harm and other, no adverse events were identified in
the small sample and a comparison was not performed.
The least severe adverse events (category E) accounted
for more than half of the adverse events identified in
both samples. Severity level including prolonged stay
accounted for the same amount (30–40%) in both
samples. No significant differences were found between
the rate of adverse events per 1000 patient days between
the samples, when adverse events were analysed separ-
ately according to severity of the adverse events:
E (RR=1.50, 95% CI 1.00 to 2.26, p=0.05) and F
(RR=1.68, 95% CI 0.99 to 2.85, p=0.05) and F, G, H and
I (RR=0.47, 95% CI 0.17 to 1.27, P=0.14) and G, H and
I (RR=1.38, 95% CI 0.87 to 2.18, p=0.17).
DISCUSSION
The rate of adverse events was 1.45 higher in the large
sample than in the small sample. Our findings indicate
that the sample size may influence the rate of identified
adverse events. The differences in CI and SE indicate
that increasing the sample size decreases the variation,
as expected. We believe that the higher rate of adverse
events detected was due to the use of a larger sample
and may be more reflective of the total population given
the size of the hospital. Since the distribution of severity
level and types of adverse events were the same in both
sample sizes, we suggest that these distributions are
unaffected by sample size.
While evaluations of the Global Trigger Tool have
reported high sensitivity3 and acceptable reliability,16 17
the impact of the sample size in determining the level of
adverse events has hardly been discussed. We believe this
is the first attempt to assess the impact of the sample
size to the rate of adverse events identified with the
Global Trigger Tool. Good et al10 adjusted the sample
size to the hospital sizes without further comparisons
between different sample sizes selected in the same time
period. We wanted to evaluate whether a larger sample
of records reviewed bi-weekly could yield higher rates of
adverse events than a sample of 10 records reviewed
bi-weekly. Our trust had increased our bi-weekly samples
to correspond to 12% of the total number of discharges
and found higher rates of adverse events than compar-
able Norwegian trusts that reviewed samples of 10
records bi-weekly. Thus we determined it legitimate,
necessary and original to assess whether using the
Global Trigger Tool with different sample sizes would
produce different results.
While our findings may challenge the sensitivity of the
recommended small sample size in order to identify an
accurate rate of adverse events, they also underline the
ability of that sample size to reflect distribution of sever-
ities and categories of adverse events accurately. Our
results in terms of this, corresponds well with other
studies.18 19 In the small sample, no adverse events of cat-
egory I were identified. This is most likely due to the fact
that the Global Trigger Tool is not designed to identify all
such cases (category I). Owing to their infrequent occur-
rence, other methods should be used to monitor these
specific types of events, for example, investigating all hos-
pital deaths.20 21 Thus, we compared the rate of adverse
events in category I along with the rate of adverse events
in other categories (category F, G and H).
Several factors could explain the differences in the rate
of adverse events identified in the two samples. First, the
authentication processes differed slightly for the two
samples. To assess for possible bias, we evaluated the
inter-rater reliability of the two teams that reviewed the
different samples. We found substantial agreement
between the two review teams regarding presence,
number and severity level of adverse events, thus con-
clude that the difference in adverse event rates between
the samples are most likely not due to bias from the
minor difference in authentication processes. These find-
ings are supported by the work of Zegers et al.22 Second,
the Simpson paradox, implying that statistical results from
aggregated data could give a different result from a
group-level analysis.23 A skewness regarding the variables
associated with the index discharges could be present in
our study, as the large sample was stratified according to
the services before sampling and the small sample was
not. However, the primary results did not differ when
adjusting for these variables. Neither did the demo-
graphic characteristics sex, age and length of stay differ
between the large and the small sample. Third, the study
was undertaken for only 1 year of discharges comprising
240 records in the small sample. A meta-analysis of differ-
ent sample sizes showed that the variation of adverse
event rates decreases as the sample size increases,4 thus
underlining the importance of having a large enough
sample size in order to obtain valid results.
CONCLUSION
We believe the findings in this study could challenge the
appropriateness of the sampling methods commonly
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used as the rate of adverse events increased when the
number of records reviewed bi-weekly was increased,
though limitations of the study must be considered. The
distributions of adverse event categories and severity
level did not differ between the samples and only the
rate of adverse events appeared to be influenced by the
sample size. Further studies are needed to determine
whether there is an optimal sample size and if it should
be based on hospital size, especially as reviewing larger
sample sizes requires more resources. Until further
studies, we suggest using a relative increase in sample
size to 8–10% of total number of discharges.
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